194 related articles for article (PubMed ID: 33594661)
1. Benefits of cardiac pacing in ICD recipients with hypertrophic cardiomyopathy.
Jiménez-Sánchez D; Castro-Urda V; Toquero-Ramos J; Restrepo-Córdoba MA; Sánchez-García M; García-Izquierdo E; Veloza D; Baena-Herrera J; González-López E; Domínguez F; García-Pavía P; Fernández-Lozano I
J Interv Card Electrophysiol; 2022 Jan; 63(1):165-174. PubMed ID: 33594661
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
3. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
4. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
Dallaglio PD; di Marco A; Moreno Weidmann Z; Perez L; Alzueta J; García-Alberola A; Fernandez-Lozano I; Díaz-Infante E; Rodriguez A; Basterra N; Calvo D; Rodriguez Garcia M; Aceña M; Anguera I
Heart Rhythm; 2020 Jul; 17(7):1084-1091. PubMed ID: 32113896
[TBL] [Abstract][Full Text] [Related]
5. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
6. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous versus transvenous implantable defibrillator in patients with hypertrophic cardiomyopathy.
Jankelson L; Garber L; Sherrid M; Massera D; Jones P; Barbhaiya C; Holmes D; Knotts R; Bernstein S; Spinelli M; Park D; Aizer A; Chinitz L
Heart Rhythm; 2022 May; 19(5):759-767. PubMed ID: 35038570
[TBL] [Abstract][Full Text] [Related]
8. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
[TBL] [Abstract][Full Text] [Related]
9. Ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Prevalence, distribution, predictors, and outcome.
Segev A; Wasserstrum Y; Arad M; Larrañaga-Moreira JM; Martinez-Veira C; Barriales-Villa R; Sabbag A
Heart Rhythm; 2023 Oct; 20(10):1385-1392. PubMed ID: 37385464
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
11. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
12. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
Magnusson P; Gadler F; Liv P; Mörner S
Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
[TBL] [Abstract][Full Text] [Related]
13. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy.
O'Mahony C; Lambiase PD; Rahman SM; Cardona M; Calcagnino M; Quarta G; Tsovolas K; Al-Shaikh S; McKenna W; Elliott P
Europace; 2012 May; 14(5):724-33. PubMed ID: 22094454
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
15. Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy.
Fumagalli C; De Filippo V; Zocchi C; Tassetti L; Marra MP; Brunetti G; Baritussio A; Cipriani A; Bauce B; Carrassa G; Maurizi N; Zampieri M; Calore C; De Lazzari M; Berteotti M; Pieragnoli P; Corrado D; Olivotto I
Int J Cardiol; 2022 Apr; 353():62-67. PubMed ID: 35031346
[TBL] [Abstract][Full Text] [Related]
16. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
18. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
[TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
[TBL] [Abstract][Full Text] [Related]
20. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
